ArticlePloS one2025
Establishment and application of an intelligent management platform for home medication for children with leukemia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of Mobile Health Interventions in Pediatric Cancer: Systematic Review and Meta-Analysis of Randomized Controlled Trials.JMIR mHealth and uHealth · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to establish an intelligent management platform for home medication for children with leukemia and verify its efficacy in enhancing home medication compliance in children with leukemia using intelligent approaches.
methodChildren with leukemia who were treated in a hospital in Chongqing, China, between January and April 2022 were enrolled. The user intentions and requirements for an intelligent management platform for home medication were analyzed for both the patient and their family, leading to the establishment of an intelligent management platform with multiple ports. Children with leukemia who were at the maintenance stage of the treatment during July-December 2023, were randomly divided into control and experimental groups. For medication management, hard copies of chemotherapy records and regular outpatient follow-up data were collected from both groups. For the experimental group, data were also acquired from the intelligent management platform. The self-efficacy in rational medication, rate of missed/incorrect administration, and unplanned admission rate of the two groups were assessed after three months of intervention. The usage efficiency of the platform was also evaluated in children and caregivers in the experimental group.
resultsThe intelligent management platform for home medication for children with leukemia comprised a patient-end WeChat applet, a medical staff-end WeChat applet, and a Web management end, with each applet having distinct functions. After three months of intervention, the self-efficacy score in rational medication of the experimental group was significantly higher than that of the control group (33.93 vs. 30.03, P < 0.05). Furthermore, the rate of missed or incorrect administration of the experimental group was significantly lower than that of the control group (10% vs. 26.76%, P < 0.05). The rates of unplanned admission of the two groups did not differ significantly (P > 0.05). Moreover, the overall satisfaction of the experimental group of children and caregivers with the proposed platform was 94.29%.
conclusionThe proposed management platform for home medication for children with leukemia was associated with increased self-efficacy in the rational medication of these children and a reduced missed/incorrect administration rate, thereby providing an effective approach for more accurate and safer home medication for these children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.